Centessa Pharmaceuticals reported a net loss of $36.8 million for the fourth quarter of 2023, with research and development expenses at $29.7 million and general and administrative expenses at $12.3 million. The company's cash, cash equivalents, and short-term investments totaled $256.5 million as of December 31, 2023, expected to fund operations into 2026.
Registrational PRESent-2 and PRESent-3 studies of SerpinPC for hemophilia B are ongoing, with PRESent-2 advancing toward an interim analysis planned in 2024.
Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers is planned in 2024.
The Phase 1/2a study of LB101 (PD-L1xCD47) for solid tumors is ongoing.
The company expects cash, cash equivalents and short-term investments will fund operations into 2026.
Centessa Pharmaceuticals is focused on advancing its key programs and expects to achieve several milestones in the near term.
Analyze how earnings announcements historically affect stock price performance